Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report.
Dipeptidyl peptidase 4 inhibitor
Glucose Clamp
Insulin Resistance
Type 2 Diabetes
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
07 Jun 2022
07 Jun 2022
Historique:
received:
24
04
2022
accepted:
29
05
2022
entrez:
7
6
2022
pubmed:
8
6
2022
medline:
8
6
2022
Statut:
epublish
Résumé
Dipeptidyl peptidase 4 inhibitor (DPP4i) is an effective medicine for type 2 diabetes mellitus (T2DM). Some articles reported DPP4i improves insulin secretion and insulin resistance. However, these effects are not well established by glucose clamp test and test meal in Japanese. We investigated the effect of DPP4i on insulin resistance and insulin secretion by using the glucose clamp test and meal tolerance test (MTT). We performed a MTT, and the hyperinsulinemic-euglycemic clamp in 8 Japanese patients with T2DM. This study was a single-arm study. We measured fasting and postprandial glucose, insulin, incretins, and glucagon levels. We also measured serum adiponectin levels. HbA1c was significantly decreased after 3 months. The fasting and postprandial glucose levels were significantly decreased. Fasting and postprandial insulin levels were not changed. The insulin resistance derived from the glucose clamp test was significantly improved. HOMA-IR was not significantly changed. GLP-1 and GIP were significantly increased but glucagon did not change. Adiponectin was not significantly changed. Although the number of patients was very small, these results suggested that DPP4i treatment might improve insulin resistance without changing insulin secretion.
Sections du résumé
BACKGROUND
BACKGROUND
Dipeptidyl peptidase 4 inhibitor (DPP4i) is an effective medicine for type 2 diabetes mellitus (T2DM). Some articles reported DPP4i improves insulin secretion and insulin resistance. However, these effects are not well established by glucose clamp test and test meal in Japanese. We investigated the effect of DPP4i on insulin resistance and insulin secretion by using the glucose clamp test and meal tolerance test (MTT).
METHODS
METHODS
We performed a MTT, and the hyperinsulinemic-euglycemic clamp in 8 Japanese patients with T2DM. This study was a single-arm study. We measured fasting and postprandial glucose, insulin, incretins, and glucagon levels. We also measured serum adiponectin levels.
RESULTS
RESULTS
HbA1c was significantly decreased after 3 months. The fasting and postprandial glucose levels were significantly decreased. Fasting and postprandial insulin levels were not changed. The insulin resistance derived from the glucose clamp test was significantly improved. HOMA-IR was not significantly changed. GLP-1 and GIP were significantly increased but glucagon did not change. Adiponectin was not significantly changed.
CONCLUSIONS
CONCLUSIONS
Although the number of patients was very small, these results suggested that DPP4i treatment might improve insulin resistance without changing insulin secretion.
Identifiants
pubmed: 35672759
doi: 10.1186/s13098-022-00850-9
pii: 10.1186/s13098-022-00850-9
pmc: PMC9171964
doi:
Types de publication
Journal Article
Langues
eng
Pagination
78Informations de copyright
© 2022. The Author(s).
Références
BMJ Open Diabetes Res Care. 2020 Apr;8(1):
pubmed: 32354719
Cardiovasc Diabetol. 2013 Jan 22;12:21
pubmed: 23339473
J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9
pubmed: 16912128
Horm Metab Res. 2004 Nov-Dec;36(11-12):867-76
pubmed: 15655721
PLoS One. 2018 Jul 20;13(7):e0201052
pubmed: 30028879
Eur J Pharmacol. 2000 Sep 15;404(1-2):239-45
pubmed: 10980284
Cardiovasc Diabetol. 2014 May 24;13:96
pubmed: 24884787
Diabetes Care. 2015 Jan;38(1):150-8
pubmed: 25538311
J Clin Endocrinol Metab. 2008 Feb;93(2):459-64
pubmed: 18042650
Diabetes Care. 2002 Nov;25(11):2081-7
pubmed: 12401760
J Clin Endocrinol Metab. 2005 Jun;90(6):3191-6
pubmed: 15769987
Diabetes Obes Metab. 2016 Nov;18(11):1100-1109
pubmed: 27300579
Diabetes Ther. 2014 Jun;5(1):285-97
pubmed: 24888256
Lancet. 2014 Mar 22;383(9922):1068-83
pubmed: 24315620
Diabetes Obes Metab. 2017 Mar;19(3):442-447
pubmed: 27800649
Metabolism. 2006 Dec;55(12):1561-3
pubmed: 17142124
Diabetologia. 2013 Apr;56(4):696-708
pubmed: 23344728
Diabetes Obes Metab. 2021 Sep;23(9):2116-2124
pubmed: 34047443
J Diabetes Investig. 2021 Oct;12(10):1805-1815
pubmed: 33751849
Diabetes Care. 2020 Mar;43(3):634-642
pubmed: 31888883
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
pubmed: 17957034
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
J Clin Endocrinol Metab. 2004 May;89(5):2078-84
pubmed: 15126524
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825